CA2136140C - Carcinostatic for hormonotherapy containing dienogest as effective component - Google Patents

Carcinostatic for hormonotherapy containing dienogest as effective component Download PDF

Info

Publication number
CA2136140C
CA2136140C CA002136140A CA2136140A CA2136140C CA 2136140 C CA2136140 C CA 2136140C CA 002136140 A CA002136140 A CA 002136140A CA 2136140 A CA2136140 A CA 2136140A CA 2136140 C CA2136140 C CA 2136140C
Authority
CA
Canada
Prior art keywords
cancer
dienogest
therapeutic agent
solvate
hormonotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002136140A
Other languages
English (en)
French (fr)
Other versions
CA2136140A1 (en
Inventor
Yasunori Shibutani
Masaomi Obata
Masami Sato
Yukio Katsuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of CA2136140A1 publication Critical patent/CA2136140A1/en
Application granted granted Critical
Publication of CA2136140C publication Critical patent/CA2136140C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002136140A 1993-11-19 1994-11-18 Carcinostatic for hormonotherapy containing dienogest as effective component Expired - Fee Related CA2136140C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5-290823 1993-11-19
JP29082393 1993-11-19

Publications (2)

Publication Number Publication Date
CA2136140A1 CA2136140A1 (en) 1995-05-20
CA2136140C true CA2136140C (en) 2007-10-30

Family

ID=17760949

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002136140A Expired - Fee Related CA2136140C (en) 1993-11-19 1994-11-18 Carcinostatic for hormonotherapy containing dienogest as effective component

Country Status (9)

Country Link
US (1) US5652231A (de)
EP (1) EP0654267B1 (de)
AT (1) ATE215826T1 (de)
AU (1) AU683098B2 (de)
CA (1) CA2136140C (de)
DE (1) DE69430356T2 (de)
DK (1) DK0654267T3 (de)
ES (1) ES2176218T3 (de)
PT (1) PT654267E (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4418102B2 (ja) * 1997-10-17 2010-02-17 持田製薬株式会社 ジエノゲストを有効成分とする子宮筋腫治療剤
AU1690399A (en) * 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Neovascularization inhibitor containing dienogest as the active ingredient
EP1043331A4 (de) * 1997-12-26 2002-05-15 Mochida Pharm Co Ltd Cytokinase inhibitor zur resorption im knochen mit dienogest als aktivem wirkstoff
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE19908762A1 (de) * 1999-02-18 2000-08-31 Jenapharm Gmbh Verwendung von Dienogest in hoher Dosierung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718872A1 (de) * 1976-06-14 1977-12-22 Jenapharm Veb Verfahren zur herstellung von neuen gona-4,9(10)-dienen
JPS6372627A (ja) * 1986-09-17 1988-04-02 Mitsubishi Kasei Corp 子宮内膜症治療薬
JPS643121A (en) * 1987-06-25 1989-01-06 Mitsubishi Kasei Corp Remedy for endometriosis
KR0181264B1 (ko) * 1989-07-07 1999-03-20 라브리 페르낭 성스테로이드 활성 억제용 안드로겐 유도체

Also Published As

Publication number Publication date
US5652231A (en) 1997-07-29
DK0654267T3 (da) 2002-05-13
EP0654267A1 (de) 1995-05-24
PT654267E (pt) 2002-09-30
CA2136140A1 (en) 1995-05-20
DE69430356T2 (de) 2002-08-14
ATE215826T1 (de) 2002-04-15
DE69430356D1 (de) 2002-05-16
AU683098B2 (en) 1997-10-30
ES2176218T3 (es) 2002-12-01
AU7888394A (en) 1995-05-25
EP0654267B1 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
RU2137476C1 (ru) Применение конкурентных антагонистов прогестерона для контрацепции, новые соединения ряда конкурентных антагонистов прогестерона
US20140288035A1 (en) 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17b-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis
NZ229392A (en) Product comprising estrogens and antiestrogens and pharmaceutical compositions containing it
JP4891479B2 (ja) ホルモン代替治療のための生物由来エストロゲンスルファメートの使用
KR20050059092A (ko) 에스트로겐 보충 요법
HUT76061A (en) Permanently ionic derivatives of steroid hormones and their antagonists, as well as pharmaceutical compositions having anticancer effect containing them
CA2136140C (en) Carcinostatic for hormonotherapy containing dienogest as effective component
JP6691193B2 (ja) プロゲステロン受容体アンタゴニスト剤形
US10369159B2 (en) Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and gynecological disease therapeutic agent using same
JP3754466B2 (ja) ジエノゲストを有効成分とするホルモン療法用制癌剤
PT1326617E (pt) Utilização de 11beta-(4-acetilfenil)-17beta-hidroxi-17alfa-(1,1,2,2-pentafluoroetil)estra-4,9-dien-3-ona para a preparação de um medicamento para o tratamento de cancro da mama, do ovário, do endométrico, mieloma e meningioma
UA113283C2 (xx) 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
CN116570593B (zh) 一种防止卵巢早衰的药物及其用途
Inoue et al. Therapeutic Value of Mepitiostane in the Treatment of Advanced Breast Cancer 1, 2
DRILL Steroids inhibiting ovulation
JPS59157023A (ja) エストロジエン欠乏状態の治療方法
Nomura et al. Therapeutic Value of Mepitiostane in the Treatment of Advanced Breast Cancer 1, 2
HO et al. ADRENALINE ANALOGUES
UA79071C2 (en) Use of conjugated estrogens and medroxyprogesterone acetate in hormone replacement therapy
TW200402298A (en) Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed